The NCCN Annual Conference: Advancing the Standard of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas.
NCCN 20th Anniversary Video - Improving Cancer Care Together
Featuring past and present leadership, this video describes the groundbreaking accomplishments of NCCN over the past two decades. more >
NCCN Keynote: 20 Years of Improving the Quality, Effectiveness, and Efficiency of Cancer Care
In this keynote address from the NCCN 20th Anniversary, Robert W. Carlson, MD, Chief Executive Officer, NCCN, describes the achievements of NCCN over the past two decades, as well as introduces new resources and advancements from NCCN that will further the mission of NCCN to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. more >
20 Years of Improving Cancer Care Together - An NCCN Roundtable Discussion
On March 12, 2015, as part of its 20th Annual Conference, NCCN featured the commemorative event, 20 Years of Improving Cancer Care Together – An NCCN Roundtable Discussion. This roundtable is sponsored by AbbVie; Astellas Pharma US, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Hologic; ImmunoGen, Inc.; Incyte Corporation; and Sigma-Tau Pharmaceuticals, Inc. Supported by an educational grant from Merck. more >
View press releases to learn about conference highlights
Enduring materials are available through the NCCN Continuing Education Portal. Topics include: Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hematologic Malignancies, Lung Cancer, Skin Cancer, and Supportive Care.
ase check back for additional information.
Supported by educational grants from Actelion; AstraZeneca; Bristol-Myers Squibb; BTG International; Celgene Corporation; Genentech BioOncology; Gilead Sciences, Medical Affairs; Lilly; Merck; Novartis Oncology; Pfizer; Prometheus Laboratories Inc.; and Takeda Oncology. This activity is supported by an independent educational grant from sanofi US. This activity was made possible by Pharmacyclics, Inc. and Janssen Biotech, Inc.
Organizations who are interested in exhibits or sponsorships are encouraged to send an e-mail to email@example.com